Neuraminidase inhibitors--the story behind the Cochrane review
dc.contributor.author | Doshi, Peter | |
dc.date.accessioned | 2017-05-25T01:18:37Z | |
dc.date.available | 2017-05-25T01:18:37Z | |
dc.date.issued | 2009-12-08 | |
dc.identifier.citation | Doshi P. (2009). Neuraminidase inhibitors--the story behind the Cochrane review. BMJ 2009;339:b5164. DOI: https://doi.org/10.1136/bmj.b5164 | en_US |
dc.identifier.uri | http://hdl.handle.net/10713/6612 | en_US |
dc.description | Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the story | en_US |
dc.description.uri | http://bmj.com/cgi/content/full/bmj.b5164?ijkey=IJj0Y9z5v4LN0Ts&keytype=ref | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.subject | neuraminidase inhibitors | en_US |
dc.subject | Tamiflu | en_US |
dc.subject | public health policy | en_US |
dc.subject | drug efficacy | en_US |
dc.subject.lcsh | Systematic reviews (Medical research) | en_US |
dc.subject.mesh | Influenza, Human--drug therapy | en_US |
dc.subject.mesh | Oseltamivir | en_US |
dc.title | Neuraminidase inhibitors--the story behind the Cochrane review | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1136/bmj.b5164 | |
dc.identifier.pmid | 19995813 | |
dc.identifier.ispublished | No | en_US |
dc.description.uriname | Click here for the free full-text article on publisher’s website | en_US |
refterms.dateFOA | 2019-02-19T18:16:27Z |